Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received the drug registration certificate for Naloxone Hydrochloride Injection from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product line [1] Group 1: Product Approval - The approval is for Naloxone Hydrochloride Injection, which is indicated for multiple uses including reversing respiratory depression caused by opioid drugs during anesthesia recovery [1] - The product can also be used to partially or completely reverse respiratory depression due to opioid overdose, rescue acute ethanol poisoning, and diagnose acute opioid overdose [1]

盐酸纳洛酮注射液的适应症为：1、用于阿片类药物复合麻醉术后，拮抗该类药物所致的呼吸抑制，促 使病人苏醒;2、用于阿片类药物过量，完全或部分逆转阿片类药物引起的呼吸抑制;3、解救急性乙醇中 毒;4、用于急性阿片类药物过量的诊断。 智通财经APP讯，华海药业(600521.SH)发布公告，公司于近日收到国家药品监督管理局核准签发的盐 酸纳洛酮注射液的《药品注册证书》。 ...

华海药业12月26日公告，公司于近日收到国家药品监督管理局核准签发的盐酸纳洛酮注射液的《药品注 册证书》。盐酸纳洛酮注射液的适应症为：1、用于阿片类药物复合麻醉术后，拮抗该类药物所致的呼 吸抑制，促使病人苏醒；2、用于阿片类药物过量，完全或部分逆转阿片类药物引起的呼吸抑制；3、解 救急性乙醇中毒；4、用于急性阿片类药物过量的诊断。 ...

Core Viewpoint - Jilin Aodong announced the approval of "Naloxone Hydrochloride Injection" by the National Medical Products Administration, which is a significant development for the company and its subsidiary [2] Group 1 - Jilin Aodong's subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd., received the approval notification for the drug [2] - The approval is for a supplemental application for "Naloxone Hydrochloride Injection," indicating potential growth in the company's product offerings [2]

Core Viewpoint - Jilin Aodong (000623.SZ) announced that its subsidiary, Yanji Pharmaceutical Group, received approval from the National Medical Products Administration for the "Naloxone Hydrochloride Injection" [1] Group 1: Product Approval - The approval is for Naloxone Hydrochloride Injection, which is an opioid receptor antagonist [1] - Indications for use include: 1. Reversal of respiratory depression caused by opioid drugs after combined anesthesia [1] 2. Complete or partial reversal of respiratory depression due to opioid overdose [1] 3. Rescue from acute ethanol poisoning [1] 4. Diagnosis of acute opioid overdose [1]

Core Viewpoint - Jilin Aodong Pharmaceutical Group's subsidiary has received approval for the "Naloxone Hydrochloride Injection" from the National Medical Products Administration, indicating a significant advancement in the company's product offerings and potential market impact [1] Group 1: Product Approval - The company announced that its subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd., has received a "Drug Supplement Application Approval Notice" for Naloxone Hydrochloride Injection [1] - The drug has passed the consistency evaluation of quality and efficacy for generic drugs, which is crucial for market entry and competitiveness [1] Group 2: Drug Indications - Naloxone Hydrochloride Injection is indicated for use in opioid-related anesthesia recovery, specifically to counteract respiratory depression caused by opioids, facilitating patient awakening [1] - The drug is also used to completely or partially reverse respiratory depression caused by opioid overdose, highlighting its critical role in emergency medical situations [1]

Core Viewpoint - The announcement indicates that the company's subsidiary, Yanji Pharmaceutical, has received approval for the "Naloxone Hydrochloride Injection" from the National Medical Products Administration, which is expected to enhance market competitiveness and expand market share, although it is not anticipated to have a significant short-term impact on the company's performance [1] Summary by Relevant Categories Product Approval - Yanji Pharmaceutical has received the approval notice for "Naloxone Hydrochloride Injection" with a specification of 1ml: 0.4mg, under the original drug approval number Guoyao Zhunzi H20066188 [1] Market Impact - The approval allows the product to pass the consistency evaluation of quality and efficacy for generic drugs, which is beneficial for increasing the product's market share and competitiveness [1] - It is expected that there will be no significant impact on the company's performance in the short term [1]

Core Viewpoint - Jilin Aodong (000623.SZ) announced that its subsidiary, Yanji Pharmaceutical Group, received approval from the National Medical Products Administration for the "Naloxone Hydrochloride Injection" [1] Group 1: Product Approval - The approval is for Naloxone Hydrochloride Injection, which is an opioid receptor antagonist [1] - Indications for use include: 1. Reversal of respiratory depression caused by opioid drugs after combined anesthesia [1] 2. Complete or partial reversal of respiratory depression due to opioid overdose [1] 3. Rescue in cases of acute ethanol poisoning [1] 4. Diagnosis of acute opioid overdose [1]

Core Viewpoint - The company, Zhongguancun, has shown a positive performance in its stock price and financial results, indicating growth potential in the pharmaceutical sector, particularly in innovative drug development and strategic product sales [1] Financial Performance - As of August 26, 2025, Zhongguancun's stock price is 5.63 yuan, up 0.36% from the previous trading day, with a trading volume of 202,400 shares and a transaction amount of 114 million yuan [1] - The company reported a revenue of 1.239 billion yuan for the first half of 2025, with a net profit attributable to shareholders of 36.85 million yuan, reflecting a year-on-year growth of 36.34% [1] - The strategic product, "Hydrochloride Oxycodone Injection," saw a revenue increase of over 90% year-on-year [1] Product and Market Development - Zhongguancun operates in the chemical pharmaceutical sector, focusing on biomedicine, health products, commercial concrete, and elderly medical care [1] - The company has key products such as "Hydrochloride Benidipine Tablets" and "Hydrochloride Oxycodone Injection," and is actively involved in innovative drug research and development [1] - The "Hydrochloride Naloxone Injection" was selected in the tenth batch of national drug centralized procurement [1] Investment Activity - On August 26, 2025, the net inflow of main funds into Zhongguancun was 3.9925 million yuan, with a cumulative net inflow of 16.9189 million yuan over the past five trading days [1]

Core Viewpoint - The company reported a slight decline in revenue but an increase in net profit, indicating effective cost management and strategic focus on core business operations [1] Financial Performance - The company achieved operating revenue of 1.239 billion yuan, a year-on-year decrease of 2.71% [1] - The net profit reached 38.81 million yuan, reflecting a year-on-year increase of 6.65% [1] - The non-recurring net profit was 36.85 million yuan, showing a significant year-on-year growth of 36.34% [1] Sales Strategy - The company continues to implement a sales strategy focused on "full product promotion, full channel expansion, and full terminal coverage," enhancing both self-operated and agency product sales [2] - Key products such as the core product "Benidipine Hydrochloride Tablets" maintained growth, while "Oxycodone Hydrochloride Injection" saw over 90% revenue growth year-on-year [2] - The successful selection of "Naloxone Hydrochloride Injection" in the national centralized procurement is expected to enhance its market coverage and performance [2] Marketing and Brand Development - The company has integrated diverse promotional methods to enhance brand awareness and has collaborated closely with major chain enterprises to improve distribution efficiency [3] - Major products like "Huasu Tablets" received recognition at health conferences, indicating strong market performance and brand influence [3] - The company won the "2024 JD Health Trend Category Award," showcasing its achievements in the health consumption sector and digital transformation efforts [3] Research and Development - The company made progress in drug research and development, with several drug applications receiving acceptance notifications from the National Medical Products Administration [4] - The health product business is advancing with marketing upgrades and participation in major dental exhibitions to expand market reach [4] - Collaborations with dental clinics are being established to further enhance product promotion and brand visibility [4]